Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2117 USD | -3.77% |
|
+3.02% | -78.06% |
06-04 | Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting | CI |
05-08 | Apollomics, Inc. Appoints Robert Lin to the Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-78.06% | 23.23M | |
+16.45% | 122B | |
+21.96% | 116B | |
+23.73% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.52% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- APLM Stock
- News Apollomics, Inc.
- HC Wainwright Adjusts Price Target on Apollomics to $17 From $18, Maintains Buy Rating